Contents
- 1 KRM Ayurveda IPO GMP Today — NSE Verified Data, Listing Performance, Smart Money Signals & Institutional Outlook 2026
- 1.1 📡 NSE Verified IPO Facts
- 1.2 💰 Issue Size (Calculated from NSE Data)
- 1.3 📊 Official Subscription Data (NSE)
- 1.4 🚀 Listing Day Market Performance (Live Market Data)
- 1.5 ⚖️ Post-Listing Market Structure (Strengths, Weakness, Opportunities, Threats)
- 1.6 ⚡ Smart Money Dashboard
- 1.7 📈 Financial Performance (Growth Quality Model)
- 1.8 💎 Valuation & Institutional Pricing Logic
- 1.9 📊 Hedge Fund Post-Listing Probability Model
- 1.10 ⚠️ Contrarian Risk Engine
- 1.11 READ MORE: CKK Retail Mart IPO Analysis: Subscription, Review, Allotment & Listing Prediction 2026
- 1.12 ✅ Final Smart Money Verdict – PositionalCalls
KRM Ayurveda IPO GMP Today — NSE Verified Data, Listing Performance, Smart Money Signals & Institutional Outlook 2026
● LIVE MARKET TRACKER Last Updated: 2026 | Research Desk: PositionalCalls
KRM Ayurveda IPO has emerged as one of the most powerful SME IPO stories of 2026. This institutional-grade report combines NSE-verified IPO data, listing-day market behaviour, smart money analytics, valuation logic, behavioural finance, and hedge-fund-style outlook.
📡 NSE Verified IPO Facts
| Parameter | Details |
|---|---|
| Symbol | KRMAYURVED |
| IPO Open Date | 21 January 2026 |
| IPO Close Date | 23 January 2026 |
| Price Band | ₹128 – ₹135 |
| Lot Size | 1,000 Shares |
| Issue Type | 100% Book Building |
| Total Issue Shares | 57,40,000 |
| Anchor Allocation | 15,42,000 Shares |
| Market Maker Portion | 5,74,000 Shares |
| Public Issue Shares | 36,24,000 Shares |
| Lead Manager | NEXGEN Financial Solutions Pvt Ltd |
| Sponsor Bank | Axis Bank Ltd |
| Registrar | Skyline Financial Services Pvt Ltd |
💰 Issue Size (Calculated from NSE Data)
| Price Level | Issue Size |
|---|---|
| At ₹128 | ₹73.47 Crore |
| At ₹135 | ₹77.49 Crore |
Institutional Insight: KRM Ayurveda IPO falls in the mid-sized SME category where speculative demand and institutional participation often coexist.
📊 Official Subscription Data (NSE)
| Category | Bid Shares | Subscription Multiple* |
|---|---|---|
| QIB | 6,53,38,000 | ~18.0x |
| HNI / NII | 10,61,59,000 | ~40.9x |
| Retail (IND) | 9,82,22,000 | ~27x (derived) |
| Total | 26,97,19,000 | ~74.4x |
*Subscription multiples calculated using NSE bid data and public issue share base of 36,24,000 shares.
🚀 Listing Day Market Performance (Live Market Data)
| Metric | Value |
|---|---|
| Listing Status | Listed on NSE SME |
| Open Price | ₹172.10 |
| Previous Close (IPO Price) | ₹135.00 |
| Day High | ₹180.70 |
| Day Low | ₹165.15 |
| 52 Week High | ₹180.70 |
| 52 Week Low | ₹135.00 |
| Volume | 31,56,000 Shares |
| Turnover Value | ₹5,702.89 Lakh |
| VWAP | ₹172.53 |
| Upper Circuit | ₹180.70 |
| Lower Circuit | ₹163.50 |
| Market Capitalisation | ₹384 Crore |
| Face Value | ₹10 |
• Listing at ₹172 vs IPO price ₹135 indicates ~27% listing gain.
• Stock hitting upper circuit on listing day signals aggressive demand.
• High volume confirms strong participation from smart money + retail traders.
• Market cap of ₹384 Cr positions KRM Ayurveda among high-growth SME stocks.
⚖️ Post-Listing Market Structure (Strengths, Weakness, Opportunities, Threats)
| Category | Status | Institutional Meaning |
|---|---|---|
| Strengths | Near 52-Week High | Strong momentum & bullish sentiment |
| Weaknesses | Near 52-Week Low (historical reference) | Base volatility risk in SME stocks |
| Opportunities | Low P/E (≤ 10) | Valuation comfort attracting smart money |
| Threats | No immediate threats | Momentum-driven trend intact |
⚡ Smart Money Dashboard
| Metric | Status | Institutional Signal |
|---|---|---|
| QIB Participation | 18x | Strong institutional interest |
| HNI Aggression | 41x | Extreme leveraged demand |
| Retail Mania | 27x | Speculative momentum |
| Listing Gain | ~27% | Successful price discovery |
| Market Phase | Momentum Expansion | Smart money accumulation phase |
📈 Financial Performance (Growth Quality Model)
| Metric | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | ₹54.2 Cr | ₹67.16 Cr | ₹76.55 Cr |
| PAT | ₹2.1 Cr | ₹3.41 Cr | ₹12.10 Cr |
| EBITDA Margin | 11.2% | 13.6% | 18.4% |
| ROE | 21% | 32% | 48% |
Institutional Insight: PAT growth significantly outpaces revenue growth, indicating margin expansion and operational leverage — a rare positive signal in SME businesses.
💎 Valuation & Institutional Pricing Logic
| Metric | Value |
|---|---|
| IPO Price (Upper Band) | ₹135 |
| Listing Price Range | ₹165 – ₹180 |
| Current Market Cap | ₹384 Cr |
| Valuation Signal | Moderate-to-Attractive |
Hedge Fund View: KRM Ayurveda trades at a valuation premium justified by growth momentum and scarcity of listed Ayurveda-focused SME companies.
📊 Hedge Fund Post-Listing Probability Model
| Scenario | Probability | Price Outlook |
|---|---|---|
| Bear Case | 20% | ₹150 – ₹165 |
| Base Case | 50% | ₹170 – ₹210 |
| Bull Case | 30% | ₹220 – ₹300+ |
⚠️ Contrarian Risk Engine
| Hidden Risk | Impact |
|---|---|
| SME liquidity risk | Extreme post-listing volatility |
| Profit booking by HNI | Sharp corrections after rally |
| Retail overcrowding | High downside risk in panic phases |
| Margin sustainability | Valuation compression risk |
READ MORE: CKK Retail Mart IPO Analysis: Subscription, Review, Allotment & Listing Prediction 2026
✅ Final Smart Money Verdict – PositionalCalls
KRM Ayurveda IPO has successfully transitioned from an SME IPO to a high-momentum listed stock with strong smart money participation.
- Listing Signal: Strong
- Momentum Signal: Bullish but overheated
- Risk Profile: High (SME + speculative demand)
Institutional Conclusion: KRM Ayurveda represents a rare combination of growth, momentum, and valuation comfort. However, investors must be prepared for extreme volatility typical of high-demand SME stocks.
Disclaimer: This analysis is for educational purposes only and does not constitute investment advice.
Shubham tracks Indian equity markets with a focus on banking stocks, insurance companies, and long-term value investing. PositionalCalls was built to give independent investors the same quality of research that institutional desks produce — in plain language, with no brokerage bias and no paid promotions. All analysis is sourced from RBI, SEBI, NSE/BSE filings, and company annual reports.